Allergan introduces Juvéderm Volux to Vycross range
Allergan's latest hyaluronic acid injectable gel uses the patented VYCROSS® technology and is specifically formulated to restore and create volume(1)
Juvéderm® VOLUX allows practitioners to sculpt the chin and jaw area,(2) giving facial definition that can last for up to 18–24 months(3)*
According to research 51% (n=1,707) of people want to reshape their chin or jawline(4)**
MONACO, April 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) –– today launched Juvéderm® VOLUX at the 17thAesthetic & Anti-Aging World Congress (AMWC) in Monaco. Juvéderm® VOLUX represents the latest innovation in Allergan's extensive range of Juvéderm® facial fillers. Juvéderm® VOLUX contains hyaluronic acid (HA) and uses the unique patented VYCROSS® technology.1,2 The product has been specially formulated to restore and create volume in the chin and jaw area2 for up to 18-24 months.3*
As we get older, several factors can contribute to how the lower face ages including genetics,5 soft tissue and bone structure changes,6 repetitive facial expressions7 and environmental elements.5 Many people start to lose definition around the chin, neck and jawline area,8 often changing the shape of the face.8
Interestingly, Allergan research shows that 51% (n = 870) of people want to change their lower face shape.4** In other research, women report the ideal lower face shape is a symmetrical, 'oval' shape with good proporation, which provides a defined jaw line with clear definition between the neck and chin area.9±
"Our face shape changes as we age: skin begins to thin and lose its plumpness, while drooping soft tissue can lead to the appearance of jowls," comments leading dermatologist Patricia Ogilvie, Germany. "Until now, non-invasive treatment options for the lower face have been limited. Juvéderm® VOLUX is the perfect solution for my patients who want a more defined look around the lower face without having to resort to surgery - the gel enables us to restore volume so that the jawline appears tauter and more defined."
The importance of facial definition
Consumer research shows that 7 in 10 (70% / n = 17,929)π of people care about the way their face looks,10 and according to many experts the appearance of the lower face can play an important role in our perceived facial attractiveness.11
Beauty is often described using three key tenets: symmetry, balance and harmony.12 Some women describe the ideal lower face shape as a defined jawline and a firm, toned chin.9±
Juvéderm® VOLUX, a structural gel, now provides a treatment option for those want to define the chin and jawline areas.1,2
Results with Juvéderm® VOLUX
In a trial Juvéderm® VOLUX delivered high satisfaction with 95% of patients (n = 85) reporting they were satisfied with the results three months after treatment.13 The setup of this study was unique as the primary goal was to evaluate the mean change in facial angle from baseline compared with a control group. At 18 months, 62% of patients (n = 79) still felt their results were positive.13
Like many other facial filler products within the Juvéderm® range, Juvéderm® VOLUX contains lidocaine for a more comfortable treatment experience.1
Marc Princen, Executive Vice President & President, International Commercial for Allergan, says: "Juvéderm® has been answering the needs of consumers for well over a decade, helping them to achieve their desired look. As the Global leader in medical aesthetics we're constantly looking to evolve our portfolio of products and technologies, and now, with Juvéderm® VOLUX, men and women around the world can achieve the defined and contoured lower face that they're looking for – allowing them to Sculpt it!"
Allergan is strongly committed to the health, safety and well-being of patients who are treated with our products. As part of the Company's ongoing commitment to medical education, Allergan is now offering training programs through its Allergan Medical Institute for healthcare professionals on the safe and effective use of this new treatment to ensure optimal patient satisfaction and outcomes.
For more information visit www.Allergan.com.
